Lymphoma Medications

Cytotoxic chemotherapy, the oldest and most commonly used type of cancer treatment, halts cell division and kills rapidly growing cells. For a full list of chemotherapy drugs, click here.

Arranon is a nucleoside inhibitor approved for refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.

Beleodaq is an HDAC inhibitor approved for relapsed or refractory peripheral T-cell lymphoma.

Xpovio is the first approved nuclear export inhibitor. It is indicated for people with previously treated relapsed or refractory (nonresponsive) multiple myeloma or diffuse large B-cell lymphoma.

Zolinza is an HDAC inhibitor approved for people with cutaneous T-cell lymphoma that does not respond to other systemic therapy.

Keytruda is a PD-1 checkpoint inhibitor approved for inoperable or metastatic melanoma, adjuvant treatment of melanoma after surgery, non-small-cell lung cancer, bladder (urothelial) cancer, head and neck cancer, esophageal cancer, liver cancer, kidney cancer, stomach cancer, classic Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, Merkel cell carcinoma, cutaneous squamous cell carcinoma and pre- and post-surgery treatment of triple-negative breast cancer. It is also approved for all metastatic solid tumors with high microsatellite instability or mismatch repair deficiency mutations (MSI-H/dMMR) or high tumor mutation burden. 

Kymriah is a CAR-T therapy approved for relapsed or refractory B-cell acute lymphoblastic leukemia in children and young adults up to age 25 and for relapsed or refractory diffuse large B-cell lymphoma in adults.

Opdivo is a checkpoint inhibitor approved for inoperable or metastatic melanoma, metastatic or recurrent non-small-cell lung cancer, advanced kidney cancer, relapsed or refractory classical Hodgkin lymphoma, recurrent or metastatic head and neck cancer, advanced or metastatic bladder (urothelial) cancer, liver cancer, advanced stomach and esophageal cancer, malignant pleural mesothelioma and colorectal cancer with high microsatellite instability or mismatch repair deficiency genetic mutations. 

Tecartus is a CAR-T therapy approved for adults with mantle cell lymphoma who have not responded to or who have relapsed after other kinds of treatment.

Yescarta is a CAR-T therapy approved for relapsed or refractory large B-cell lymphoma in adults, including diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma, and for follicular lymphoma.

Adcetris is a CD30-directed antibody-drug conjugate approved for anaplastic large cell lymphoma and classical Hodgkin lymphoma.

Aliqopa is a PI3K kinase inhibitor approved for relapsed follicular lymphoma.

Arzerra is a monoclonal antibody approved for chronic lymphocytic leukemia, and used for the similar blood cancer small lymphocytic lymphoma, alone or in combination with chemotherapy.

Brukinsa is a BTK kinase inhibitor approved the previously treated adults with mantle cell lymphoma.

Calquence is a BTK kinase inhibitor approved for mantle cell lymphoma and as a first-line or subsequent treatment for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL).

Copiktra is a PI3K kinase inhibitor approved for relapsed or refractory chronic lymphocytic leukemia, small lymphocytic lymphoma and follicular lymphoma.

Gazyva is a monoclonal antibody approved for follicular lymphoma and chronic lymphocytic leukemia, and used for the similar blood cancer small lymphocytic lymphoma, in combination with chemotherapy.

Imbruvica is a BTK kinase inhibitor approved for mantle cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, mantle cell lymphoma, marginal zone lymphoma and Waldenstrom macroglobulinemia. It is also used to treat graft-versus-host disease, which can occur after a stem cell transplant.

Monjuvi is a CD19-directed monoclonal antibody approved for the treatment of relapsed or refractory (nonresponsive) diffuse large B-cell lymphoma in combination with Revlimid (lenalidomide).

Polivy is a CD79b-directed antibody-drug conjugate approved for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in combination with bendamustine and a rituximab product such as Rituxan.

Rituxan is a monoclonal antibody approved for follicular lymphoma, diffuse large B-cell lymphoma and chronic lymphocytic leukemia, and used for the similar blood cancer small lymphocytic lymphoma, alone or in combination with chemotherapy. Truxima and Ruxience are biosimilar medications.

Tazverik is an EZH2 methyltransferase inhibitor approved for the treatment of inoperable epithelioid sarcoma (a type of soft tissue cancer) and for relapsed or refractory follicular lymphoma.

Velcade is a proteasome inhibitor approved for multiple myeloma and mantle cell lymphoma.

Venclexta is a BCL-2 inhibitor approved for the treatment of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in previously treated patients, first-line treatment of CLL or SLL in combination with Gazyva (obinutuzumab) and acute myeloid leukemia in patients who can't use intensive chemotherapy.

Xalkori is a kinase inhibitor approved for the treatment of ALK- or ROS1-positive metastatic non-small-cell lung cancer (NSCLC) and for children and young adults with relapsed or refractory ALK-positive anaplastic large cell lymphoma.

Zydelig is a PI3K kinase inhibitor approved for relapsed follicular lymphoma, relapsed chronic lymphocytic leukemia and relapsed small lymphocytic lymphoma.